鲁抗医药
(600789)
| 流通市值：72.03亿 | | | 总市值：74.52亿 |
| 流通股本：10.10亿 | | | 总股本：10.45亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,602,900,179.29 | 3,237,764,932.37 | 1,616,445,518.8 | 5,766,115,536.79 |
| 营业收入 | 4,602,900,179.29 | 3,237,764,932.37 | 1,616,445,518.8 | 5,766,115,536.79 |
| 二、营业总成本 | 4,433,623,196.65 | 3,074,854,999.75 | 1,540,488,548.05 | 5,618,182,381.98 |
| 营业成本 | 3,637,885,006.18 | 2,519,746,217.65 | 1,271,923,786.59 | 4,493,270,340.99 |
| 税金及附加 | 44,702,915.15 | 29,731,576.53 | 12,218,795.52 | 57,739,562.44 |
| 销售费用 | 279,627,539.24 | 217,171,319.17 | 106,267,184.18 | 454,363,808.93 |
| 管理费用 | 192,872,277.21 | 126,537,688.86 | 63,622,255.54 | 256,552,999.56 |
| 研发费用 | 223,649,839.92 | 142,637,581.16 | 64,316,007.14 | 299,148,500.45 |
| 财务费用 | 54,885,618.95 | 39,030,616.38 | 22,140,519.08 | 57,107,169.61 |
| 其中:利息费用 | 37,093,038.69 | 25,336,308.2 | 13,495,571.23 | 65,786,010.12 |
| 其中:利息收入 | 7,689,981.5 | 5,147,453.91 | 2,435,846.88 | 10,508,226.77 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 0 | - | -71,340 |
| 加:投资收益 | -5,104,152.53 | -2,801,782.35 | -1,206,775.25 | -5,220,411.67 |
| 资产处置收益 | 100,378.21 | 1,946.9 | 2,118.65 | 168,153.08 |
| 资产减值损失(新) | -27,323,763.83 | -23,751,147.07 | -13,653,528.2 | -45,731,523.35 |
| 信用减值损失(新) | -14,007,623.41 | -15,257,787.38 | -7,283,041.16 | -6,183,101.51 |
| 其他收益 | 62,682,089.4 | 34,408,448.47 | 12,316,808.61 | 69,677,109.87 |
| 四、营业利润 | 185,623,910.48 | 155,509,611.19 | 66,132,553.4 | 160,572,041.23 |
| 加:营业外收入 | 5,465,506.19 | 1,308,236.58 | 1,165,455.18 | 5,322,631.94 |
| 减:营业外支出 | 1,389,479.86 | 901,108.45 | 558,938.96 | 4,687,553.08 |
| 五、利润总额 | 189,699,936.81 | 155,916,739.32 | 66,739,069.62 | 161,207,120.09 |
| 减:所得税费用 | 13,784,747.88 | 9,929,643.17 | 10,204,670.02 | 49,300,753.06 |
| 六、净利润 | 175,915,188.93 | 145,987,096.15 | 56,534,399.6 | 111,906,367.03 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 175,915,188.93 | 145,987,096.15 | 56,534,399.6 | 111,906,367.03 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 165,187,891.4 | 138,147,236.4 | 53,253,383.31 | 112,304,823.56 |
| 少数股东损益 | 10,727,297.53 | 7,839,859.75 | 3,281,016.29 | -398,456.53 |
| 扣除非经常损益后的净利润 | 123,169,340.74 | 116,158,555.03 | 45,690,315.83 | 83,450,732.97 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.13 | 0.05 | 0.12 |
| (二)稀释每股收益 | 0.16 | 0.13 | 0.05 | 0.12 |
| 八、其他综合收益 | -3,092,246.97 | 223,988.93 | -454,273.62 | -2,413,737.03 |
| 归属于母公司股东的其他综合收益 | -3,092,246.97 | 223,988.93 | -454,273.62 | -2,413,737.03 |
| 九、综合收益总额 | 172,822,941.96 | 146,211,085.08 | 56,080,125.98 | 109,492,630 |
| 归属于母公司股东的综合收益总额 | 162,095,644.43 | 138,371,225.33 | 52,799,109.69 | 109,891,086.53 |
| 归属于少数股东的综合收益总额 | 10,727,297.53 | 7,839,859.75 | 3,281,016.29 | -398,456.53 |
| 公告日期 | 2026-10-29 | 2026-08-29 | 2026-04-25 | 2026-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |